Home > News content

Head of nearly 100 million goodwill too beautiful science and technology on the science and technology innovation board play

via:新浪科技     time:2021/12/31 15:02:39     readed:89

  

The head of nearly 100 million goodwill too Beautiful science and technology on the science and technology innovation board play

Eight years after its establishment, Zhao Lu, the actual controller, will lead Zhejiang Taimei Medical Technology Co., LTD. (hereinafter referred to as "Taimei Technology") to enter the A-share capital market and seek the first share of pharmaceutical SaaS. Taimei Technology's IPO has been accepted and the company plans to raise 2 billion yuan, according to the Shanghai Stock Exchange website. However, in the case of not yet profitable, Taimei technology is still head of 97,008,000 yuan of goodwill; In terms of the whole year, taimei technology's r&d investment ratio from 2018 to 2020 also decreased year by year.

  97,008,000 yuan goodwill

As of the end of the first half of this year, Taimei technology account of goodwill up to 97,008 million yuan.

Learned, too the United States is the leading science and technology based on cloud computing and big data technology of life science industry digital solution providers, products and services cover clinical research, pharmacovigilance, pharmaceutical marketing, during the reporting period, the company mainly sales of independent research and development of clinical research, pharmacovigilance, SaaS in the field of pharmaceutical marketing and other products, And based on the advantages of digital technology, to provide professional services in related fields.

To the prospectus signing date, Zhao Lu total direct and indirect control of the company 69.7789% of voting rights.

Financial data show that from 2018 to 2020 and in the first half of 2021, Taimei Technology achieved operating revenue of about 59.9743 million yuan, 187 million yuan, 303 million yuan and 188 million yuan respectively. Corresponding realized attributable net profit is about -183 million yuan, -389 million yuan, -524 million yuan, -158 million yuan respectively; The corresponding attributable net profit after deduction is about -144 million yuan, -153 million yuan, -266 million yuan and -231 million yuan respectively.

It is not difficult to see that, according to the whole year, too the United States of science and technology losses in the range of increasing. Taimei technology said that as of the end of the reporting period, the company has not yet made a profit and there is an accumulated loss, mainly due to research and development expenses, stock payment expenses and high labor costs in the reporting period.

While not yet profitable, Taimei technology has a lot of goodwill on its books. According to Taimei Technology, as of June 30, 2021, the company's goodwill book value is 97,008,000 yuan, including the goodwill book value generated by the acquisition of Soft Element Technology and Nuoming Technology are 75.528,400 yuan and 21.479,600 yuan, respectively.

It is understood that taimei Technology acquired Asusoft Technology and Naoming Technology in 2019, at that time, a total of 161 million yuan of goodwill was formed. However, due to the operating performance of Asusoft Technology did not reach the amount promised at the time of acquisition, the company has withdrawn 29.483,500 yuan and 34.634,200 yuan of goodwill impairment losses at the end of 2020 and the end of June 2021 respectively.

Investment and financing expert Xu Xiaoheng told Beijing Business Daily that it is not uncommon for A shares to erode the performance of goodwill, and the goodwill on the account of IPO enterprises is the focus of regulatory attention, which is easy to lead to the performance of enterprises after listing "face change".

In response to relevant questions, a reporter from Beijing Business Daily sent an interview letter to taimei's board of Directors office. Taimei said in the reply, "Affected by the prosperity of the downstream pharmaceutical industry, if the macroeconomic environment continues to deteriorate or the pharmaceutical industry policy is tightened and the demand trend declines, Or the failure of Usoft and Nomin to effectively improve their research and development capabilities to launch new products or customer expansion as expected may result in goodwill impairment losses for UsOft and Nomin in the future ".

  The proportion of r&d investment has been falling year by year

For the whole year, taimei technology r&d investment accounted for a lower proportion year by year.

Data show that from 2018 to 2020, Taimei Technology research and development expenses were 40.5294 million yuan, 83.709 million yuan, 109 million yuan, research and development investment increased year by year, but the proportion of revenue is declining, research and development expenses during the reporting period accounted for 67.58%, 44.67%, 35.98% of the operating revenue of each period.

Taimei technology in an interview with Beijing Business Daily said that the company's RESEARCH and development expenses are mainly composed of employee salaries, which accounted for a relatively high proportion of the 2018 revenue scale is small.

According to Taimei Technology, since its establishment in 2013, the company has always attached great importance to the construction of the R&D team, and the size of the R&D team continues to expand. By the end of the first half of 2021, the company has 406 r&d personnel, accounting for 30.25% of the total number of employees, including 5 core technical personnel. Independent economist Wang Chikun told Beijing Business Daily that, as a technology innovation company, its RESEARCH and development investment has been a focus of regulatory attention, the specific reasons for the annual decline in the proportion of enterprises may need to explain in detail.

Although the proportion of R&D investment is decreasing year by year, TMAC is still higher than the average of comparable public companies. According to the prospectus, from 2018 to 2020, taimei's average R&D expense ratio of comparable listed companies was 75.1%, 23.56% and 16.86%, respectively.

Taimei technology related person told Beijing Business Daily that the company's R&D expense ratio is higher than the average of comparable companies, mainly because the company is in a period of rapid development, attaches great importance to the research and development of new products, more RESEARCH and development projects, the number of research and development personnel growth, the overall research and development investment to maintain rapid growth, accounting for a high proportion of revenue.

In the first half of this year, Taimei technology spent 80,904,900 yuan on R&D, accounting for 42.99 percent of its revenue in the period.

In addition to the proportion of RESEARCH and development investment decreased year by year, taimei technology's main business gross margin performance is not ideal. During 2018-2020 and the first half of 2021, taimei's main business gross margin was 38.61%, 47.44%, 40.94% and 39.24% respectively.

Too the United States science and technology, said the company's main business gross margin level is sales revenue by product competitiveness, and the change of the human cost, the influence of the purchasing cost change, the company is in rapid development period, the differences between the various business gross margin, if in the future the company gross margins lower than rising business accounted for, or have failed to keep competitive advantage in market competition, Both will lead to a decline in the company's gross margin, which will adversely affect the company's profitability.

Seeking to be listed on the science innovation Board, Taimei Technology plans to raise 2 billion yuan, invested in the clinical research intelligent collaboration platform upgrade project, clinical research enterprise end system r&d and upgrading project, independent image evaluation system r&d and upgrading project and pharmacovigilance system r&d and upgrading project.

Reporter of Beijing Business Daily & NBSP; The horse for a change

translate engine: Youdao

China IT News APP

Download China IT News APP

Please rate this news

The average score will be displayed after you score.

Post comment

Do not see clearly? Click for a new code.

User comments